Anti-aging research becomes much easier to think about when it is broken into the hallmarks of aging rather than collapsed into one giant promise. Telomere attrition, mitochondrial dysfunction, genomic instability, altered nutrient sensing, and immunosenescence are not the same problem. The best longevity compound depends on which of those questions your protocol is actually trying to answer.

That is why NAD+, Epithalon, MOTS-C, Vitamin B12, GHK-Cu, and Thymosin Alpha 1 can all belong in the same conversation without being interchangeable. They sit inside different aging frames, which is exactly what a useful roundup should make visible.

1. NAD+ — broadest cross-lab visibility in mitochondrial, redox, and sirtuin-linked research.
2. Thymosin Alpha 1 — strongest clinical footprint in immune contexts, relevant to immunosenescence questions.
3. GHK-Cu — meaningful when the aging question centers on gene expression, remodeling, or resilience signatures.
4. MOTS-C — increasingly important when the protocol targets mitochondrial signaling and exercise-linked aging biology.
5. Epithalon — most useful when the protocol is explicitly about telomere and telomerase questions.

Some protocols are cleaner when they isolate one hallmark: NAD+ for mitochondrial stress, Epithalon for telomere-linked questions, or MOTS-C for AMPK and exercise-mimetic signaling. Other protocols are built around the multi-hallmark idea — the possibility that two or three aging pathways should be studied together because aging itself is layered.

That multi-hallmark logic is scientifically attractive, but it also raises the bar for interpretation. Once multiple compounds enter the same design, the protocol must decide whether the goal is synergy, complementarity, or simply coverage across aging mechanisms. The more explicit that decision is, the stronger the study becomes.